{"id":"W2163238468","doi":"10.1016/j.amjcard.2014.05.060","title":"Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)","year":2014,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université du Québec à Chicoutimi","funders":"Amgen","keywords":"Alirocumab; PCSK9; Medicine; Placebo; Internal medicine; Lipoprotein(a); Kexin; Evolocumab; Lipoprotein; Dosing; Endocrinology; Gastroenterology; Cholesterol; LDL receptor; Apolipoprotein A1; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008939464,0.0003251407,0.004818984,0.0004921326,0.0001003846,0.00001421088,0.0003172351,0.00009896291,0.0000483177],"category_scores_gemma":[0.001740575,0.0001928584,0.002455873,0.0007903111,0.0008221452,0.00007406677,0.0000460059,0.0005599286,0.00000273911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001005602,"about_ca_system_score_gemma":0.0003770042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001953342,"about_ca_topic_score_gemma":0.00001276881,"domain_scores_codex":[0.9906371,0.006139003,0.001659211,0.000320292,0.000862592,0.0003817965],"domain_scores_gemma":[0.9940186,0.001751843,0.002573602,0.0009378388,0.0004681452,0.0002499792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04551715,0.0004348484,0.01609761,0.0002055666,0.05272492,0.0002682123,0.0006875194,0.005831311,0.4342422,0.0002686607,0.0001608267,0.4435612],"study_design_scores_gemma":[0.08214559,0.09137772,0.1394816,0.001658174,0.128519,0.001825074,0.001226249,0.01189195,0.5369512,0.0006616752,0.002990223,0.001271555],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796907,0.001153134,0.01715172,0.0005517782,0.0002019712,0.0009846969,0.0001200576,0.00001283545,0.0001331027],"genre_scores_gemma":[0.9978418,0.000213837,0.00047517,0.0002628027,0.001075695,0.00002207834,0.0000725254,0.00002987467,0.00000616553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4422896,"threshold_uncertainty_score":0.7864537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01740808616805861,"score_gpt":0.3518448448536979,"score_spread":0.3344367586856393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}